- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02813850
Oxygen Therapy and Pregnancy in Sickle Cell Disease (DRO2G)
Impact of Home-based Oxygen Therapy on Maternal and Fetal Complications, in Pregnant Women With Sickle Cell Disease. A Randomized Multi-center Trial.
Study Overview
Detailed Description
Sickle cell disease (SCD) corresponds to a group of inherited disorders with clinical manifestations resulting from the biochemical consequences of a single-base substitution of valine by glutamic acid at position 6 of the ß-hemoglobin (Hb) subunit (HbA [ß6val] to HbS [ß6glu]). When the oxygen tension is low, the solubility of HbS falls and the molecules polymerize. In turn, the intracellular formation of HbS polymers results in red blood cell (RBC) sickling. The aggregation of sickle cells is responsible for the vaso-occlusive crises (VOCs) that characterize SCD.
Thanks to improvements in the management of SCD patients, over 95% of affected infants survive to adulthood. Pregnancy is a high-risk situation for women with sickle cell disease, especially in the third trimester, during delivery and in the post-partum period. Conversely sickle cell disease can lead to pregnancy complications for both mother and fetus since maternal-fetal mortality remains elevated.
RBC transfusions and careful prevention of infections represent the only available treatments in this situation.
The complexity of this setting and the associated therapeutic strategy is further accentuated by the high frequency of post-transfusion side effects during SCD pregnancies, can indirectly affect the newborn by inducing hypoxia, and may ultimately prevent the woman from receiving further transfusions (RCOG, 2015) (Tuck et al, 1983). Post-transfusion complications constitute negative prognostic factors that affect both the mother's health and fetal development and thus increase the risk of premature death.
Another factor complicating the outcome of the pregnancy is the increase in oxygen demand in order to satisfy the increased metabolic requirements of the placenta and fetus. As the maternal oxygen reserve can be compromised during pregnancy for several reasons (such as the increased oxygen consumption, the SCD related anemia accentuated by the plasmatic increase), patients are particularly susceptible to hypoxemia - leading to the exacerbation of sickling events and SCD-related complications. (Hill & Pickinpaugh, 2008)(Thame et al, 2007)(Rathod et al, 2007a)(Cines et al, 1998)(Hassell, 2005)(Pantanowitz et al, 2000)(Rathod et al, 2007b) Moving from this observation, the first innovative approach introduced was the widespread use of prophylactic oxygen treatment at home. The rationale behind this change came from experiments on a murine model of SCD mice, in which a high-oxygen environment during pregnancy was associated with a lower prenatal fetal/maternal mortality rate (Ye et al, 2008). The absence of severe complications was also noticed in some women who could not be transfused (because of severe alloimmunization) and who were already receiving oxygen therapy at home before pregnancy.
Then a preliminary retrospective study was performed to evaluate the clinical benefit of the widespread use of prophylactic oxygen treatment at home. It indicates that this innovative treatment is safe and seems to be associated with a significant decrease in the transfusion rate in SCD patients during pregnancy.
These findings are encouraging, but they are preliminary and bias have to be taken into account. These results have to be confirmed by a randomized trial.
The project aim is to assess preventive oxygen therapy impact on women with sickle cell disease, their fetal and their newborn. Firstly, investigators want to assess preventive home-based oxygen therapy efficacy for preventing vaso-occlusive complications which last 24 hours and require a hospitalization. Secondly, they want to assess oxygen therapy impact on prevention and characteristics of obstetrical complications, prevention of neonatal complications, fetal and newborn's characteristics, type of medical care, transfusion balance sheet, way of transfusion and maternal, fetal and newborn tolerability of home-based oxygen therapy during pregnancy.
For this they propose to analyze 200 pregnant SCD women. 100 women in the first arm with standard medical care. 100 women in the second arm who will have home-based oxygen therapy early at night.
This study will be performed in 9 French hospitals. Blood samples of SCD women and blood cord will be drawn to monitor red cell adherence protein expression and function and their mechanic and adhesive properties.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hôpital Necker Enfants-Malades (Public Hospitals of Paris)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant women from 18 to 50 years old
- Maximal term: 20SA
- Patient with sickle cell disease
- Consent form signed by the patient
- Affiliated or beneficiary of a health insurance regimen and State Medical Aid.
Exclusion Criteria:
- Patients with transfusion restrictions
- Patients whose house can not receive the device
- Patients who have a weekly use of prophylactic oxygen therapy at home
- Patients who don't understand the operating instructions *Include patients with a doctor's prescription only. The portable oxygen concentrator will be removed from patients' home at the initiation visit prior to the overnight home oximetry test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control
standard medical care
|
|
Experimental: oxygen therapy
|
Oxygen therapy early in the night (2L/min) during 4hours per days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of at least one vaso-occlusive complication which last more than 24h
Time Frame: 30 days postpartum
|
Painful vaso-occlusive episodes in bones, acute chest syndrome, ischemic stroke, cardiomyopathy, pulmonary hypertension, splenic and hepatic sequestration, death of the mother
|
30 days postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of at least one vaso-occlusive complication which last more than 24h
Time Frame: 30 days postpartum
|
Painful vaso-occlusive episodes in bones, acute chest syndrome, ischemic stroke, cardiomyopathy, pulmonary hypertension, splenic and hepatic sequestration, death of the mother
|
30 days postpartum
|
Occurrence of pregnancy-induced hypertension, pre-eclampsia, eclampsia
Time Frame: 20 months
|
20 months
|
|
Occurence of hospitalisation because of premature delivery risk
Time Frame: 20 months
|
20 months
|
|
Occurence of late miscarriage
Time Frame: 20 months
|
20 months
|
|
Occurence of Preterm (<35SA) and very preterm ( from 26 to 32SA)
Time Frame: 20 months
|
20 months
|
|
Type of delivery (vaginal, active, caesarean)
Time Frame: 20 months
|
20 months
|
|
Number of days hospitalisation postpartum
Time Frame: 20 months
|
20 months
|
|
Occurence of Neonatal complications ( respiratory distress, analgesics withdrawal symptom)
Time Frame: 20 months
|
20 months
|
|
Number of days of hospitalisation for the newborn
Time Frame: 20 months
|
20 months
|
|
Number of days of hospitalisation in resuscitation unit for the newborn
Time Frame: 20 months
|
20 months
|
|
Newborn weight
Time Frame: 20 months
|
20 months
|
|
Newborn size
Time Frame: 20 months
|
20 months
|
|
Newborn head circumference
Time Frame: 20 months
|
20 months
|
|
Apgar score assess 1 min after birth
Time Frame: 20 months
|
20 months
|
|
Apgar score assess 5 min after birth
Time Frame: 20 months
|
20 months
|
|
Apgar score assess 10 min after birth
Time Frame: 20 months
|
20 months
|
|
Perinatal and neonatal death
Time Frame: 20 months
|
20 months
|
|
pH of of the newborn
Time Frame: 20 months
|
20 months
|
|
Lactate of of the newborn
Time Frame: 20 months
|
20 months
|
|
Number of days using painkiller (level II and III) during pregnancy
Time Frame: 20 months
|
20 months
|
|
Number of urgent consultation
Time Frame: 20 months
|
20 months
|
|
Number of days of hospitalisation and hospitalisation in intensive care during pregnancy
Time Frame: 20 months
|
20 months
|
|
Stage of pregnancy at the first transfusion
Time Frame: 20 months
|
20 months
|
|
Total volume of transfusion during pregnancy
Time Frame: 20 months
|
20 months
|
|
Way of transfusion: simple, bleeding-transfusion, erythrocytapheresis
Time Frame: 20 months
|
20 months
|
|
Maternal, fetal and newborn tolerability of home-based oxygen therapy during pregnancy
Time Frame: 20 months
|
20 months
|
Collaborators and Investigators
Investigators
- Study Director: Alexandra BENACHI, MD, PhD, Assistance Publique - Hôpitaux de Paris
- Principal Investigator: Laure JOSEPH, MD,PhD, Assistance Publique - Hôpitaux de Paris
- Principal Investigator: Marina CAVAZZANA, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P140030
- 2015-A01276-43 (Registry Identifier: ID RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on oxygen therapy
-
Bayside HealthMonash University; Baker Heart and Diabetes Institute; Ambulance Victoria; FALCK...UnknownCoronary Artery Disease | Acute Myocardial InfarctionAustralia
-
Aalborg University HospitalUniversity of AarhusUnknownCardiac Surgery | Cardiopulmonary Bypass | Acute Lung Injury | Hyperoxia | Oxygen ToxicityDenmark
-
Cairo UniversityActive, not recruiting
-
The First Affiliated Hospital of Zhejiang Chinese...Not yet recruitingCOVID-19 | Cognitive Decline | SARS CoV 2 InfectionChina
-
Monash UniversityRecruitingFibrotic Interstitial Lung DiseaseAustralia
-
Ain Shams UniversityRecruitingOxygen Therapy | Pulmonary ResectionEgypt
-
UMC UtrechtThe Netherlands Cancer InstituteCompletedBreast Cancer | Radiation ToxicityNetherlands
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Omar AljitawiCompleted
-
University of ZurichActive, not recruitingPulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Vascular DisorderSwitzerland